Illumina Stock News

Illumina, Inc. (NASDAQ:ILMN ) UBS MedTech, Tools and Genomics Summit 2023 Conference Transcript August 17, 2023 12:00 PM ET Executives Salli Schwartz - Vice President, Investor Relations Analysts John

Illumina is facing a slew of issues due to a botched acquisition. It's also not growing very quickly.

SAN DIEGO , Aug. 11, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its vice president of investor relations will be speaking at the following investor conference: UBS MedTech

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

The U.S. Securities and Exchange Commission (SEC) has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail , the gene sequencing company said in a regul

Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.

Citi analyst Patrick Donnelly cut his price target on Illumina to $150 from $180.

Illumina, Inc. (NASDAQ:ILMN ) Q2 2023 Results Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Charles Dadswell - Interim C

While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare t

Illumina (ILMN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.57 per share a year ago.

Shares of Illumina Inc. slid 6.6% after hours on Wednesday after the DNA-sequencing company tempered its full-year sales outlook, amid a cautious consumer backdrop and a wobbly economic recovery in Ch

Illumina Inc lowered annual profit forecast on Wednesday, signaling weak demand for its sequencing and diagnostic services, sending the life sciences firm's shares down 7.5% after the bell.

As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new

Illumina (ILMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

As the 2023 stock-market rally continues, this is a good time to look further ahead to see which companies are expected to show the highest growth rates through 2025.